Items where authors include "Ellis, S"

Article

Croft, J, Ellis, S, Sherborne, AL et al. (19 more authors) (2021) Copy number evolution and its relationship with patient outcome—an analysis of 178 matched presentation-relapse tumor pairs from the Myeloma XI trial. Leukemia, 35 (7). pp. 2043-2053. ISSN 0887-6924

Shah, V, Sherborne, AL, Johnson, DC et al. (16 more authors) (2020) Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients. Leukemia, 34. pp. 3091-3096. ISSN 0887-6924

Ovtchinnikov, E, Brown, R, Kolbitsch, C et al. (17 more authors) (2020) SIRF: Synergistic Image Reconstruction Framework. Computer Physics Communications, 249. 107087. ISSN 0010-4655

Leebens-Mack, JH, Barker, MS, Carpenter, EJ et al. (191 more authors) (2019) One thousand plant transcriptomes and the phylogenomics of green plants. Nature, 574. pp. 679-685. ISSN 0028-0836

Jones, JR, Weinhold, N, Ashby, C et al. (19 more authors) (2019) Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, 104 (7). pp. 1440-1450. ISSN 0390-6078

Dennis, M, Mead, G, Forbes, J et al. (1294 more authors) (2019) Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial. The Lancet, 393 (10168). pp. 265-274. ISSN 0140-6736

Shah, V, Johnson, DC, Sherborne, AL et al. (19 more authors) (2018) Subclonal TP53 copy number is associated with prognosis in multiple myeloma. Blood, 132 (23). pp. 2465-2469. ISSN 0006-4971

Doheny-Adams, T, Lilley, CJ, Barker, A et al. (6 more authors) (2018) Constant Isothiocyanate-Release Potentials across Biofumigant Seeding Rates. Journal of agricultural and food chemistry, 66 (20). pp. 5108-5116. ISSN 0021-8561

Shah, V, Sherborne, AL, Walker, BA et al. (19 more authors) (2017) Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1,905 trial patients. Leukemia, 32. pp. 102-110. ISSN 0887-6924

Proceedings Paper

Shah, V, Johnson, DC, Sherborne, AL et al. (18 more authors) (2018) Characterisation of Long-Term Responders to First-Line Myeloma Therapy - Results from the UK Myeloma IX and XI Trials. In: Blood. 60th ASH Annual Meeting, 01-04 Dec 2018, San Diego, California, USA. American Society of Hematology , p. 2000.

Sherborne, AL, Shah, V, Ellis, S et al. (15 more authors) (2017) Improving Outcomes for Patients with High-Risk Myeloma Via Prospective Trial Evidence: The Myeloma UK Nine Optimum Trial. In: Blood. 59th ASH Annual Meeting and Exposition, 09-12 Dec 2017, Atlanta, GA, USA. American Society of Hematology , p. 1767.